A rare case of recurrent intrahepatic cholestasis of pregnancy with prolonged postpartum hepatic inflammation despite normalization of bile acid levels

Pir Ahmad Shah, Akira Nishio, Sharika Hasan, Lily Wu, Lucy Chie, Barbara Rehermann, Daryl T-Y Lau

PII: S2772-5723(22)00152-2
DOI: https://doi.org/10.1016/j.gastha.2022.08.011
Reference: GASTHA 181

To appear in: Gastro Hep Advances

Received Date: 30 July 2022
Revised Date: 29 August 2022
Accepted Date: 31 August 2022

Please cite this article as: Shah PA, Nishio A, Hasan S, Wu L, Chie L, Rehermann B, T-Y Lau D, A rare case of recurrent intrahepatic cholestasis of pregnancy with prolonged postpartum hepatic inflammation despite normalization of bile acid levels, Gastro Hep Advances (2022), doi: https://doi.org/10.1016/j.gastha.2022.08.011.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier, Inc on behalf of the AGA Institute
A rare case of recurrent intrahepatic cholestasis of pregnancy with prolonged postpartum hepatic inflammation despite normalization of bile acid levels

Pir Ahmad Shah¹,²†, Akira Nishio³,⁴†, Sharika Hasan³, Lily Wu⁵, Lucy Chie⁵, Barbara Rehermann³*, Daryl T-Y Lau¹†

¹ Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
² Department of Medicine, University of Texas Health Science Center at San Antonio, TX, United States (current affiliation)
³ Immunology Section, Liver Diseases Branch, NIDDK, National Institutes of Health, Bethesda, MD, United States
⁴ Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan (current affiliation)
⁵ Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

† Equal first author contribution
* Joint senior author contribution

Corresponding author:
Daryl T-Y Lau, MD, MSc, MPH
Director, Translational Liver Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
Associate Professor of Medicine, Harvard Medical School

Liver Center,
110 Francis Street, Suite 4A
Boston, MA, USA, 02118
Tel: (617) 331-2275
Email: dlau@bidmc.harvard.edu

Conflict of Interest statement:
PAS, AN, SH, LW, LC, BR and DTYL declare that they have no conflict of interest.

Funding source:
This work was supported by the NIH Bench-to-Bedside award (to B.R. and D.L.) and the intramural research program of NIDDK, NIH.

Ethical Statement:
The corresponding author, on behalf of all authors, jointly and severally, certifies that their institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.
Abstract

Intrahepatic cholestasis of pregnancy (ICP) is one of the most common liver diseases during second and third trimester of pregnancy, but its pathogenesis remains unclear. ICP is associated with elevations of maternal bile acids, serum aminotransferases and adverse fetal outcomes. Besides direct cytotoxic liver injury by bile acids, it has been suggested that bile acid-induced oxidative stress and mitochondrial injury lead to a cascade of inflammatory response. Here, we demonstrate that the extended elevation of serum aminotransferases after normalization of bile acid levels coincides with an extended increase of the chemokine CXCL10 and inflammatory cytokines.

Introduction

Intrahepatic cholestasis of pregnancy (ICP) usually presents during second and early third trimester of pregnancy and can lead to preterm birth, respiratory distress syndrome and still birth. [1] It is characterized by elevated bile acid levels and pruritus. The elevated serum bile acids and amino acid transferases typically normalize postpartum. However, ICP can recur during subsequent pregnancy in 60-70% of the cases. [2] Our patient presented with recurrent ICP. This case is atypical for her serum aminotransferases increased during postpartum despite normalization of bile acids in both pregnancies. We examined serial cytokine levels as an attempt to understand the persistent inflammatory response.

Case Report

The patient was a 31-year-old Chinese female with no family history of ICP or preexisting liver condition. During her first pregnancy, she experienced pruritus associated with significant elevation of bile acids to 170 umol/L and mild ALT increase at about 20-week gestation. [Figure 1A] ICP was diagnosed, and she was promptly started on ursodeoxycholic acid (UDCA). Bile acids levels decreased, and pruritus resolved. The patient had a spontaneous delivery at 30-week gestation. UDCA was discontinued after delivery and bile acids completely normalized by week-6 postpartum. ALT, however, increased to >200 U/L and persisted at >100 U/L for prolonged period after delivery. Liver biopsy at 26-week postpartum reported nonspecific inflammation with no fibrosis or steatosis. ALT finally normalized by 55 weeks postpartum.

Four years later, the patient had a second pregnancy with asymptomatic elevation of bile acids at 14-week gestation. By 26-week gestation, ALT and bile acids increased to 68 U/L and 20.8 umol/L respectively. [Figure 1B] She experienced mild pruritus in bilateral feet and UDCA was initiated. The bile acid levels increased further to 53.5 umol/L despite UDCA treatment. Induced labor was planned at 37-week gestation and the delivery was uneventful. UDCA was discontinued postpartum. At 3-week postpartum, ALT increased to 259 U/L even though bile acids continued to decrease. About 1 week after restarting UDCA, ALT decreased to 62 U/L and bile acids completely normalized. The patient became non-compliant between 8 and 12-week postpartum; ALT increased to 159 U/L but bile acids stayed normal. After counseling, patient took UDCA without interruption and ALT normalized by 18-week postpartum and remained within normal range off therapy up to week 29.

Serial plasma samples were prospectively collected from this patient and from three other pregnant Asian women without ICP. Cytokines were measured using the V- PLEX Human Cytokine 36-Plex Kit (Mesoscale Discovery, Rockville, MD). Plasma CXCL10, IL-12p40 and IL-
10 levels were higher in the patient with ICP than in the three controls without ICP during the 3rd trimester and postpartum. [Figure 2] Of note, the chemokine CXCL10 increased in parallel to the bile acid rise and prior to the ALT increase in the third trimester. In contrast, IFN-γ and IL-10 levels peaked after the peak ALT. As ALT levels decreased, levels of all cytokines except IL12 returned to baseline. The plasma concentration of IL-12 remained at high levels for more than 12 months postpartum.

Discussion

ICP is significantly more frequent in South Asia (0.8%-1.46%) and South America (9.2%-15.6%) than in Europe (0.1% to 0.2%).[3] The pathophysiology of ICP is complex involving genetic susceptibility and environmental risk factors. Genetic predisposition has been linked to mutations in the bile acid transporter genes ABCB4, ABCB11, ABCC2. [4] Mutations in the coding sequence of these genes may result in impaired transport of cytotoxic bile acids out of hepatocytes. This effect can possibly be exaggerated during pregnancy due to elevated levels of estrogen and progesterone which further impair the transport of bile acids. [2,5] ICP with serum bile acid elevation to >40 umol/L confers a 1.5 and 3-times increased risk of preterm and still birth, respectively.[6] These complications could be related to accumulation of bile acids in fetal organs. Timely management with close monitoring and induced delivery between 37-39 weeks is crucial to prevent adverse fetal outcome. [7] There were controversial reports on the beneficial effects of UDCA in fetal outcomes. [8,9,10] The decision to initiate UDCA in this case, especially its prolonged use during the second pregnancy, was an attempt to improve serum aminotransferases in addition to the potential benefits on the fetus.

In the typical ICP setting, serum bile acids and aminotransferases usually normalize within 1-3 months after delivery and UDCA therapy can be discontinued. [7] Significant and prolonged postpartum ALT elevation despite normalization of bile acid levels, as in the case described here, is highly unusual. The pathogenesis of ICP is not fully understood. Previously, the cholestatic liver injury was believed to be related to the direct cytotoxic effects or the apoptosis of hepatocytes of bile acids. [11] Recent studies of ICP-related liver injury provided evidence that the elevated bile acid levels in the hepatocytes cause oxidative stress and mitochondrial injury. The DNA released by the injured mitochondria, in turn, activates the TLR9 signaling pathway. This may lead to synthesis of proinflammatory cytokines in hepatocytes [11,12,13].

Our observation that the chemokine CXCL10 level increased in parallel with bile acid levels is in agreement with the published report. [13] We hypothesize that the elevated bile acids lead to hepatic recruitment of immune cells which express the CXCR3 receptors for CXCL10. The subsequent immune cell activation with release of IFN-γ may maintain the inflammatory response and contribute to the prolonged ALT elevation even after the bile acid levels returned to normal. In our patient, the ALT levels normalized with a prolonged postpartum course of UDCA treatment. That could be the results of the anti-apoptotic and endotoxin disposal effects of UDCA. [14] Thus, in atypical ICP cases such as ours, individualized and prolonged UDCA therapy should be considered.

References

5. Reyes H. Hepatology 2008; 47: 376-379
Figure. 1: Clinical course of primary and recurrent ICP during two subsequent pregnancies in the same patient

Serum bile acid levels and alanine aminotransferase activity in the patient with recurrent ICP during her (A) first pregnancy and (B) second pregnancy. Increased ALT activity persists despite normalization of bile acid levels. UDCA, ursodeoxycholic acid therapy
Figure 2: Chemokine and cytokine response associated with recurrent ICP.
Serial serum levels of the (A) chemokine CXCL10, cytokines (B) IL-12p40, (C) IFN-γ and (D) IL-10 of the patient with recurrent ICP are shown as bold lines during her second pregnancy. The corresponding levels in three control patients without ICP are shown as grey lines (open circle, open triangle and filled circle). The dotted red line indicates the ALT activity of the patient with ICP.